PD-L1 expression in peripheral T-cell lymphomas is not related to either PD-L1 gene amplification or rearrangements
- 7 February 2021
- journal article
- research article
- Published by Taylor & Francis Ltd in Leukemia & Lymphoma
- Vol. 62 (7), 1648-1656
- https://doi.org/10.1080/10428194.2021.1881511
Abstract
Nodal peripheral T-cell lymphomas (n-PTCL) are aggressive lymphomas with no specific treatment. Programmed death 1 (PD-1) inhibits T-cell activation and proliferation, and the expression of its ligand PD-L1 has been associated with worse prognosis in some tumors. We performed immunohistochemistry for PD-1, p-STAT3, and PD-L1 (Clones SP142/263/22C3/28.8) and FISH studies for PD-L1/2 genes in chromosome 9p in a series of 168 formalin-fixed, paraffin-embedded n-PTCL samples. PD-L1 (clone 263) was the most frequently detected in both tumor cells (especially in the ALCL subgroup) and the microenvironment (especially in the AITL subgroup). In five ALCL cases, 3–4 copies of the two loci of chromosome 9 were found, suggestive of polyploidy. PD-L1 correlated with p-STAT3 on tumor cells. PD-1 expression in tumor cells was related to expression of PD-L1 in microenvironment. The expression of PD-L1 on tumor cells or microenvironment suggests that some n-PTCL cases might benefit from immune check-point modulation therapy.Funding Information
- Instituto de Salud Carlos III (ISCIII) of the Spanish Ministry of Economy and Competitiveness
This publication has 51 references indexed in Scilit:
- The role of pembrolizumab in relapsed/refractory primary mediastinal large B-cell lymphomaTherapeutic Advances in Hematology, 2019
- Checkpoint Inhibitors Hodgkin Lymphoma and Non-Hodgkin LymphomaCurrent Hematologic Malignancy Reports, 2018
- Genetic alterations of 9p24 in lymphomas and their impact for cancer (immuno-)therapyVirchows Archiv A Pathological Anatomy and Histopathology, 2018
- PD-1–PD-L1 immune-checkpoint blockade in B-cell lymphomasNature Reviews Clinical Oncology, 2016
- Molecular Pathways: Next-Generation Immunotherapy—Inhibiting Programmed Death-Ligand 1 and Programmed Death-1Clinical Cancer Research, 2012
- Constitutive AP-1 Activity and EBV Infection Induce PD-L1 in Hodgkin Lymphomas and Posttransplant Lymphoproliferative Disorders: Implications for Targeted TherapyClinical Cancer Research, 2012
- International Peripheral T-Cell and Natural Killer/T-Cell Lymphoma Study: Pathology Findings and Clinical OutcomesJournal of Clinical Oncology, 2008
- Inhibitory B7-family molecules in the tumour microenvironmentNature Reviews Immunology, 2008
- PD-1 and Its Ligands in Tolerance and ImmunityAnnual Review of Immunology, 2008
- T-cell non-Hodgkin lymphomaBlood, 2006